Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Paclitaxel, carboplatino e bevacizumab o paclitaxel, carboplatino e temsirolimus o ixabepilone, carboplatino e bevacizumab nel trattamento di pazienti con carcinoma endometriale in stadio III, stadio IV o ricorrente

11 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio randomizzato di fase II a tre bracci su Paclitaxel/Carboplatino/Bevacizumab (NSC #704865), Paclitaxel/Carboplatino/Temsirolimus (NSC #683864) e Ixabepilone (NSC #710428)/Carboplatino/Bevacizumab come terapia iniziale per lo stadio III misurabile o IVA, Stadio IVB, o carcinoma endometriale ricorrente

This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which treatment regimen is most effective in treating patients with endometrial cancer.

Panoramica dello studio

Stato

Attivo, non reclutante

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To estimate the hazard of progression or death of each of the three arms relative to that of historical controls in patients with advanced or recurrent endometrial cancer.

SECONDARY OBJECTIVES:

I. To determine the nature, frequency, and maximum degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v)3.0 for each of the three arms.

II. To estimate the distribution of the duration of overall survival for each of the three arms.

III. To estimate the proportion of patients with measurable disease who have confirmed objective tumor responses by treatment.

TERTIARY OBJECTIVES:

I. Explore the associations between select biomarkers and progression-free survival as well as secondary measures of clinical outcome (overall survival, tumor response, or disease status if possible) in the context of histologic cell type and treatment.

IA. Somatic mutations in phosphatase and tensin homolog (PTEN)/ phosphoinositide-3-kinase (PI3K) and RAS pathway members by Sequenom mutational profiling and targeted sequencing of candidate genes.

IB. Microsatellite instability by analysis of five National Cancer Institute consensus microsatellite markers (BAT25, BAT26, D2S2123, D5S346, and D17S250) using the Applied Biosystems (ABI) Prism 3100 Genetic Analyzer.

IC. Copy number alterations (gains or losses) by array comparative genomic hybridization (aCGH).

ID. Tumor expression of PTEN and class III beta-tubulin using immunohistochemistry.

IE. Concentration of vascular endothelial growth factor (VEGF) in pre-cycle 1 plasma using an enzyme-linked immunosorbent assay.

II. Explore the relationship among the various biomarkers by histologic subtype and treatment.

III. Explore which combination of biomarkers and clinical covariates optimally predicts responsiveness and resistance to the three treatment arms.

OUTLINE: Patients are randomized to 1 of 3 treatment arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.

ARM II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus* IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients receive temsirolimus IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive temsirolimus beginning on course 2.

ARM III: Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.

After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

349

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85013
        • Saint Joseph's Hospital and Medical Center
      • Scottsdale, Arizona, Stati Uniti, 85259
        • Mayo Clinic in Arizona
      • Tucson, Arizona, Stati Uniti, 85719
        • University of Arizona Cancer Center-North Campus
    • California
      • Burbank, California, Stati Uniti, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Concord, California, Stati Uniti, 94520
        • John Muir Medical Center-Concord
      • La Jolla, California, Stati Uniti, 92093
        • UC San Diego Moores Cancer Center
      • Los Angeles, California, Stati Uniti, 90095
        • UCLA / Jonsson Comprehensive Cancer Center
      • Mountain View, California, Stati Uniti, 94040
        • Palo Alto Medical Foundation-Gynecologic Oncology
      • San Diego, California, Stati Uniti, 92103
        • UC San Diego Medical Center - Hillcrest
      • San Diego, California, Stati Uniti, 92161
        • San Diego VA Medical Center
      • San Francisco, California, Stati Uniti, 94115
        • UCSF Medical Center-Mount Zion
      • Walnut Creek, California, Stati Uniti, 94598
        • John Muir Medical Center-Walnut Creek
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • UCHealth University of Colorado Hospital
      • Englewood, Colorado, Stati Uniti, 80110
        • Rocky Mountain Gynecologic Oncology PC
    • Connecticut
      • Hartford, Connecticut, Stati Uniti, 06105
        • Smilow Cancer Hospital Care Center at Saint Francis
      • Hartford, Connecticut, Stati Uniti, 06102
        • Hartford Hospital
      • New Britain, Connecticut, Stati Uniti, 06050
        • The Hospital of Central Connecticut
      • New Haven, Connecticut, Stati Uniti, 06520
        • Yale University
    • Delaware
      • Lewes, Delaware, Stati Uniti, 19958
        • Beebe Medical Center
      • Newark, Delaware, Stati Uniti, 19718
        • Christiana Care Health System-Christiana Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • MedStar Washington Hospital Center
    • Florida
      • Clearwater, Florida, Stati Uniti, 33756
        • Morton Plant Hospital
      • Jacksonville, Florida, Stati Uniti, 32224-9980
        • Mayo Clinic in Florida
      • Miami, Florida, Stati Uniti, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Orlando, Florida, Stati Uniti, 32806
        • Orlando Health Cancer Institute
      • Orlando, Florida, Stati Uniti, 32803
        • AdventHealth Orlando
    • Georgia
      • Macon, Georgia, Stati Uniti, 31201
        • Central Georgia Gynecologic Oncology
      • Savannah, Georgia, Stati Uniti, 31404
        • Memorial Health University Medical Center
    • Hawaii
      • Honolulu, Hawaii, Stati Uniti, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, Stati Uniti, 96817
        • The Cancer Center of Hawaii-Liliha
      • Honolulu, Hawaii, Stati Uniti, 96813
        • Hawaii Cancer Care Inc - Waterfront Plaza
      • Honolulu, Hawaii, Stati Uniti, 96813
        • Straub Clinic and Hospital
      • Honolulu, Hawaii, Stati Uniti, 96813
        • University of Hawaii Cancer Center
      • Honolulu, Hawaii, Stati Uniti, 96817
        • Queen's Cancer Center - Kuakini
      • Honolulu, Hawaii, Stati Uniti, 96826
        • Kapiolani Medical Center for Women and Children
      • Lihue, Hawaii, Stati Uniti, 96766
        • Wilcox Memorial Hospital and Kauai Medical Clinic
      • Wailuku, Hawaii, Stati Uniti, 96793
        • Maui Memorial Medical Center
      • Wailuku, Hawaii, Stati Uniti, 96793
        • Pacific Cancer Institute of Maui
      • ‘Aiea, Hawaii, Stati Uniti, 96701
        • Pali Momi Medical Center
    • Idaho
      • Boise, Idaho, Stati Uniti, 83706
        • Saint Alphonsus Cancer Care Center-Boise
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Northwestern University
      • Chicago, Illinois, Stati Uniti, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Stati Uniti, 60612
        • Rush MD Anderson Cancer Center
      • Elgin, Illinois, Stati Uniti, 60123
        • Advocate Sherman Hospital
      • Hinsdale, Illinois, Stati Uniti, 60521
        • Hinsdale Hematology Oncology Associates Incorporated
      • Hinsdale, Illinois, Stati Uniti, 60521
        • Sudarshan K Sharma MD Limited-Gynecologic Oncology
    • Indiana
      • Elkhart, Indiana, Stati Uniti, 46515
        • Elkhart General Hospital
      • Elkhart, Indiana, Stati Uniti, 46514
        • Michiana Hematology Oncology PC-Elkhart
      • Elkhart, Indiana, Stati Uniti, 46514-2098
        • Elkhart Clinic
      • Indianapolis, Indiana, Stati Uniti, 46260
        • Ascension Saint Vincent Indianapolis Hospital
      • Kokomo, Indiana, Stati Uniti, 46904
        • Community Howard Regional Health
      • La Porte, Indiana, Stati Uniti, 46350
        • IU Health La Porte Hospital
      • Mishawaka, Indiana, Stati Uniti, 46545
        • Michiana Hematology Oncology PC-Mishawaka
      • Mishawaka, Indiana, Stati Uniti, 46545
        • Saint Joseph Regional Medical Center-Mishawaka
      • Plymouth, Indiana, Stati Uniti, 46563
        • Michiana Hematology Oncology PC-Plymouth
      • South Bend, Indiana, Stati Uniti, 46601
        • Memorial Hospital of South Bend
      • South Bend, Indiana, Stati Uniti, 46628
        • Northern Indiana Cancer Research Consortium
      • South Bend, Indiana, Stati Uniti, 46617
        • South Bend Clinic
      • Westville, Indiana, Stati Uniti, 46391
        • Michiana Hematology Oncology PC-Westville
    • Iowa
      • Ames, Iowa, Stati Uniti, 50010
        • McFarland Clinic - Ames
      • Clive, Iowa, Stati Uniti, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, Stati Uniti, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, Stati Uniti, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, Stati Uniti, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Stati Uniti, 50316
        • Iowa Lutheran Hospital
      • Des Moines, Iowa, Stati Uniti, 50309
        • Iowa-Wide Oncology Research Coalition NCORP
      • Des Moines, Iowa, Stati Uniti, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, Stati Uniti, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Iowa City, Iowa, Stati Uniti, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • West Des Moines, Iowa, Stati Uniti, 50266-7700
        • Methodist West Hospital
      • West Des Moines, Iowa, Stati Uniti, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Chanute, Kansas, Stati Uniti, 66720
        • Cancer Center of Kansas - Chanute
      • Dodge City, Kansas, Stati Uniti, 67801
        • Cancer Center of Kansas - Dodge City
      • El Dorado, Kansas, Stati Uniti, 67042
        • Cancer Center of Kansas - El Dorado
      • Fort Scott, Kansas, Stati Uniti, 66701
        • Cancer Center of Kansas - Fort Scott
      • Independence, Kansas, Stati Uniti, 67301
        • Cancer Center of Kansas-Independence
      • Kansas City, Kansas, Stati Uniti, 66160
        • University of Kansas Cancer Center
      • Kingman, Kansas, Stati Uniti, 67068
        • Cancer Center of Kansas-Kingman
      • Lawrence, Kansas, Stati Uniti, 66044
        • Lawrence Memorial Hospital
      • Liberal, Kansas, Stati Uniti, 67905
        • Cancer Center of Kansas-Liberal
      • McPherson, Kansas, Stati Uniti, 67460
        • Cancer Center of Kansas - McPherson
      • Newton, Kansas, Stati Uniti, 67114
        • Cancer Center of Kansas - Newton
      • Parsons, Kansas, Stati Uniti, 67357
        • Cancer Center of Kansas - Parsons
      • Pratt, Kansas, Stati Uniti, 67124
        • Cancer Center of Kansas - Pratt
      • Salina, Kansas, Stati Uniti, 67401
        • Cancer Center of Kansas - Salina
      • Wellington, Kansas, Stati Uniti, 67152
        • Cancer Center of Kansas - Wellington
      • Wichita, Kansas, Stati Uniti, 67214
        • Ascension Via Christi Hospitals Wichita
      • Wichita, Kansas, Stati Uniti, 67208
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, Stati Uniti, 67214
        • Cancer Center of Kansas - Wichita
      • Wichita, Kansas, Stati Uniti, 67208
        • Associates In Womens Health
      • Wichita, Kansas, Stati Uniti, 67214
        • Wichita NCI Community Oncology Research Program
      • Winfield, Kansas, Stati Uniti, 67156
        • Cancer Center of Kansas - Winfield
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536
        • University of Kentucky/Markey Cancer Center
      • Lexington, Kentucky, Stati Uniti, 40503
        • Baptist Health Lexington
      • Louisville, Kentucky, Stati Uniti, 40202
        • The James Graham Brown Cancer Center at University of Louisville
    • Maine
      • Portland, Maine, Stati Uniti, 04102
        • MaineHealth Maine Medical Center - Portland
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21237
        • MedStar Franklin Square Medical Center/Weinberg Cancer Institute
      • Baltimore, Maryland, Stati Uniti, 21215
        • Sinai Hospital of Baltimore
      • Baltimore, Maryland, Stati Uniti, 21204
        • Greater Baltimore Medical Center
      • Elkton, Maryland, Stati Uniti, 21921
        • Christiana Care - Union Hospital
    • Massachusetts
      • Springfield, Massachusetts, Stati Uniti, 01199
        • Baystate Medical Center
      • Worcester, Massachusetts, Stati Uniti, 01605
        • UMass Memorial Medical Center - Memorial Division
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48106
        • Michigan Cancer Research Consortium NCORP
      • Ann Arbor, Michigan, Stati Uniti, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Dearborn, Michigan, Stati Uniti, 48124
        • Corewell Health Dearborn Hospital
      • Detroit, Michigan, Stati Uniti, 48236
        • Henry Ford Health Saint John Hospital
      • Flint, Michigan, Stati Uniti, 48532
        • Genesys Regional Medical Center-West Flint Campus
      • Flint, Michigan, Stati Uniti, 48503
        • Hurley Medical Center
      • Jackson, Michigan, Stati Uniti, 49201
        • Allegiance Health
      • Kalamazoo, Michigan, Stati Uniti, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, Stati Uniti, 49007
        • Bronson Methodist Hospital
      • Kalamazoo, Michigan, Stati Uniti, 49048
        • Beacon Kalamazoo
      • Lansing, Michigan, Stati Uniti, 48912
        • University of Michigan Health - Sparrow Lansing
      • Livonia, Michigan, Stati Uniti, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Niles, Michigan, Stati Uniti, 49120
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Pontiac, Michigan, Stati Uniti, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Port Huron, Michigan, Stati Uniti, 48060
        • Lake Huron Medical Center
      • Royal Oak, Michigan, Stati Uniti, 48073
        • Corewell Health William Beaumont University Hospital
      • Saginaw, Michigan, Stati Uniti, 48601
        • MyMichigan Medical Center Saginaw
      • Saint Joseph, Michigan, Stati Uniti, 49085
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, Stati Uniti, 49085
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Warren, Michigan, Stati Uniti, 48093
        • Henry Ford Health Warren Hospital
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Mayo Clinic in Rochester
    • Mississippi
      • Jackson, Mississippi, Stati Uniti, 39216
        • University of Mississippi Medical Center
      • Jackson, Mississippi, Stati Uniti, 39216
        • Saint Dominic-Jackson Memorial Hospital
      • Pascagoula, Mississippi, Stati Uniti, 39581
        • Singing River Hospital
    • Missouri
      • Columbia, Missouri, Stati Uniti, 65212
        • MU Health - University Hospital/Ellis Fischel Cancer Center
      • Rolla, Missouri, Stati Uniti, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Springfield, Missouri, Stati Uniti, 65804
        • Cancer Research for the Ozarks NCORP
      • Springfield, Missouri, Stati Uniti, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Stati Uniti, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Stati Uniti, 63104
        • SSM Health Saint Louis University Hospital
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68114
        • Nebraska Methodist Hospital
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89106
        • Women's Cancer Center of Nevada
      • Reno, Nevada, Stati Uniti, 89502
        • Renown Regional Medical Center
      • Reno, Nevada, Stati Uniti, 89502
        • Center of Hope at Renown Medical Center
    • New Jersey
      • Camden, New Jersey, Stati Uniti, 08103
        • Cooper Hospital University Medical Center
      • Morristown, New Jersey, Stati Uniti, 07960
        • Morristown Medical Center
      • Mount Holly, New Jersey, Stati Uniti, 08060
        • Virtua Memorial
      • Newark, New Jersey, Stati Uniti, 07101
        • Rutgers New Jersey Medical School
      • Phillipsburg, New Jersey, Stati Uniti, 08865
        • Saint Luke's Hospital-Warren Campus
      • Summit, New Jersey, Stati Uniti, 07902
        • Overlook Hospital
      • Voorhees Township, New Jersey, Stati Uniti, 08043
        • Virtua Voorhees
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87106
        • Southwest Gynecologic Oncology Associates Inc
      • Albuquerque, New Mexico, Stati Uniti, 87106
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Stati Uniti, 12208
        • Women's Cancer Care Associates LLC
      • Brightwaters, New York, Stati Uniti, 11718
        • Island Gynecologic Oncology
      • Brooklyn, New York, Stati Uniti, 11203
        • State University of New York Downstate Medical Center
      • Buffalo, New York, Stati Uniti, 14263
        • Roswell Park Cancer Institute
      • Fresh Meadows, New York, Stati Uniti, 11365
        • New York Hospital Medical Center of Queens
      • New York, New York, Stati Uniti, 10065
        • Memorial Sloan Kettering Cancer Center
      • Stony Brook, New York, Stati Uniti, 11794
        • Stony Brook University Medical Center
    • North Carolina
      • Asheville, North Carolina, Stati Uniti, 28816
        • Hope Women's Cancer Centers-Asheville
      • Burlington, North Carolina, Stati Uniti, 27215
        • Cone Health Cancer Center at Alamance Regional
      • Charlotte, North Carolina, Stati Uniti, 28203
        • Carolinas Medical Center/Levine Cancer Institute
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Novant Health Presbyterian Medical Center
      • Durham, North Carolina, Stati Uniti, 27710
        • Duke University Medical Center
      • Winston-Salem, North Carolina, Stati Uniti, 27157
        • Wake Forest University Health Sciences
    • Ohio
      • Akron, Ohio, Stati Uniti, 44307
        • Cleveland Clinic Akron General
      • Akron, Ohio, Stati Uniti, 44304
        • Summa Health System - Akron Campus
      • Cincinnati, Ohio, Stati Uniti, 45219
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cleveland, Ohio, Stati Uniti, 44106
        • Case Western Reserve University
      • Cleveland, Ohio, Stati Uniti, 44109
        • MetroHealth Medical Center
      • Cleveland, Ohio, Stati Uniti, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Stati Uniti, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, Stati Uniti, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Stati Uniti, 43210
        • Ohio State University Comprehensive Cancer Center
      • Dayton, Ohio, Stati Uniti, 45409
        • Miami Valley Hospital
      • Kettering, Ohio, Stati Uniti, 45429
        • Kettering Medical Center
      • Mayfield Heights, Ohio, Stati Uniti, 44124
        • Hillcrest Hospital Cancer Center
      • Mentor, Ohio, Stati Uniti, 44060
        • UH Seidman Cancer Center at Lake Health Mentor Campus
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • University of Oklahoma Health Sciences Center
      • Tulsa, Oklahoma, Stati Uniti, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Pennsylvania
      • Abington, Pennsylvania, Stati Uniti, 19001
        • Jefferson Abington Hospital
      • Allentown, Pennsylvania, Stati Uniti, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Danville, Pennsylvania, Stati Uniti, 17822
        • Geisinger Medical Center
      • Hazleton, Pennsylvania, Stati Uniti, 18201
        • Geisinger Medical Center-Cancer Center Hazleton
      • Hershey, Pennsylvania, Stati Uniti, 17033-0850
        • Penn State Milton S Hershey Medical Center
      • Philadelphia, Pennsylvania, Stati Uniti, 19111
        • Fox Chase Cancer Center
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Pennsylvania Hospital
      • State College, Pennsylvania, Stati Uniti, 16801
        • Geisinger Medical Group
      • West Reading, Pennsylvania, Stati Uniti, 19611
        • Reading Hospital
      • Wilkes-Barre, Pennsylvania, Stati Uniti, 18711
        • Geisinger Wyoming Valley/Henry Cancer Center
    • Rhode Island
      • Providence, Rhode Island, Stati Uniti, 02905
        • Women and Infants Hospital
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29425
        • Medical University of South Carolina
      • Columbia, South Carolina, Stati Uniti, 29210
        • South Carolina Oncology Associates PA
    • South Dakota
      • Sioux Falls, South Dakota, Stati Uniti, 57105
        • Avera Cancer Institute
      • Sioux Falls, South Dakota, Stati Uniti, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, Stati Uniti, 57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Vanderbilt University/Ingram Cancer Center
    • Texas
      • Dallas, Texas, Stati Uniti, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, Stati Uniti, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Dallas, Texas, Stati Uniti, 75390
        • Clements University Hospital
      • Galveston, Texas, Stati Uniti, 77555-0565
        • University of Texas Medical Branch
      • Houston, Texas, Stati Uniti, 77026-1967
        • Lyndon Baines Johnson General Hospital
      • Houston, Texas, Stati Uniti, 77030
        • UT MD Anderson Cancer Center
      • Temple, Texas, Stati Uniti, 76508
        • Scott and White Memorial Hospital
    • Vermont
      • Burlington, Vermont, Stati Uniti, 05401
        • University of Vermont Medical Center
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • University of Virginia Cancer Center
      • Hampton, Virginia, Stati Uniti, 23666
        • Virginia Oncology Associates-Hampton
      • Norfolk, Virginia, Stati Uniti, 23502
        • Virginia Oncology Associates - Norfolk
      • Richmond, Virginia, Stati Uniti, 23298
        • VCU Massey Comprehensive Cancer Center
      • Roanoke, Virginia, Stati Uniti, 24033
        • Carilion Roanoke Memorial Hospital
    • Washington
      • Bellingham, Washington, Stati Uniti, 98226
        • PeaceHealth Medical Group PC
      • Everett, Washington, Stati Uniti, 98201
        • Providence Regional Cancer Partnership
      • Mount Vernon, Washington, Stati Uniti, 98274
        • Skagit Regional Health Cancer Care Center
      • Poulsbo, Washington, Stati Uniti, 98370
        • Harrison HealthPartners Hematology and Oncology-Poulsbo
      • Seattle, Washington, Stati Uniti, 98122
        • Swedish Medical Center-First Hill
      • Seattle, Washington, Stati Uniti, 98195
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, Stati Uniti, 98112
        • Kaiser Permanente Washington
      • Seattle, Washington, Stati Uniti, 98104
        • Pacific Gynecology Specialists
      • Seattle, Washington, Stati Uniti, 98109
        • Fred Hutchinson Cancer Center
      • Seattle, Washington, Stati Uniti, 98133
        • University of Washington Medical Center - Northwest
      • Sequim, Washington, Stati Uniti, 98384
        • Olympic Medical Cancer Care Center
      • Silverdale, Washington, Stati Uniti, 98383
        • Saint Joseph Medical Center Hematology and Oncology - Silverdale
      • Spokane, Washington, Stati Uniti, 99202
        • Cancer Care Northwest - Spokane South
      • Spokane, Washington, Stati Uniti, 99204
        • MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
      • Tacoma, Washington, Stati Uniti, 98405
        • MultiCare Tacoma General Hospital
      • Tacoma, Washington, Stati Uniti, 98405
        • Saint Joseph Medical Center
      • Walla Walla, Washington, Stati Uniti, 99362
        • Providence Saint Mary Regional Cancer Center
      • Wenatchee, Washington, Stati Uniti, 98801
        • Wenatchee Valley Hospital and Clinics
    • Wisconsin
      • La Crosse, Wisconsin, Stati Uniti, 54601
        • Gundersen Lutheran Medical Center
      • Madison, Wisconsin, Stati Uniti, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, Stati Uniti, 53233
        • Aurora Sinai Medical Center
      • Oshkosh, Wisconsin, Stati Uniti, 54904
        • Vince Lombardi Cancer Clinic - Oshkosh
      • Sheboygan, Wisconsin, Stati Uniti, 53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • West Allis, Wisconsin, Stati Uniti, 53227
        • Aurora West Allis Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Patients must have measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma

    • Histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, and transitional cell carcinoma
  • Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI

  • Patients must have Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

  • Patients must not be eligible for a higher priority GOG protocol, if one exists; in general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population

  • Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl equivalent to Common Terminology Criteria (CTCAE v3.0) grade 1

  • Platelets greater than or equal to 100,000/mcl

  • Creatinine less than or equal to 1.5 times institutional upper limit normal (ULN), CTCAE v3.0 grade 1

  • Bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1)

  • Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)

  • Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)

  • Urine protein creatinine (UPC) ratio must be < 1.0 gram (gm); if UPC ratio >= 1, collection of 24-hour urine measurement of urine protein is recommended (24-hour urine protein level must be < 1000 mg for patient enrollment)

    • UPC ratio of spot urine is an estimation of the 24 urine protein excretion

      • A UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm
  • Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =< 1.5 x ULN

  • Fasting cholesterol less than 300 mg/dL (CTCAE v3.0 grade 1)

  • Fasting triglycerides =< 2.5 x ULN (CTCAE v3.0 grade 1)

  • Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma

  • Patients must NOT have received prior therapy with bevacizumab or other VEGF pathway targeted therapy; patients must NOT have received prior therapy with temsirolimus, everolimus, ridaforolimus, sirolimus, or any other PI3K/ v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycins (mTor) pathway targeted therapy

  • Patients may have receive prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy; the prior radiation field, radiation dose, number of fractions and prior radiation start and stop dates must be provided on the Fast Fact Sheet (FFS) at registration

  • Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy

  • Patients must have signed an approved informed consent and authorization permitting release of personal health information

Exclusion Criteria:

  • Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, and other specific malignancies as noted below, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy

  • Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease

  • Patients who have received prior chemotherapy for any abdominal or pelvic tumor within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease

  • Patients with serious, non-healing wound, ulcer, or bone fracture; this includes history of abdominal/pelvic fistula, gastrointestinal perforation or intra-abdominal abscess within 3 months prior to the first date of study therapy; patients with underlying lesions that caused the fistula or perforation in the past that have not been corrected

  • Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels

  • Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy or any brain metastases

  • Patients with clinically significant cardiovascular disease; this includes:

    • Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg
    • Myocardial infarction or unstable angina within 6 months of the first date of study therapy
    • New York Heart Association (NYHA) class II or greater congestive heart failure
    • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
    • CTCAE grade 2 or greater peripheral vascular disease.
    • History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of study therapy.
    • Aortic aneurysm and/or history of aortic dissection
  • Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies

  • Patients undergoing invasive procedures as defined below:

    • Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab or temsirolimus therapy
    • Major surgical procedure anticipated during the course of the study.
    • Minor surgical procedures, fine needle aspirates, or core biopsies within 7 days prior to the first date of study therapy
  • Patients with known prior history of interstitial pneumonitis

  • Patients with CTCAE v. 3, grade 2 or greater hypoxemia

  • Patients with CTCAE v. 3, grade 2 or greater dyspnea

  • Patients must not have uncontrolled diabetes, and must not have baseline hemoglobin A1C (HgbA1C) > 8

  • Patients with peripheral neuropathy > CTCAE v.3, grade 1

  • Patients who are pregnant or nursing

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm I (paclitaxel, carboplatin, bevacizumab)

Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Given IV

Altri nomi:
  • Tassolo
  • Anzatax
  • Asotax
  • Bristaxolo
  • Praxel
  • Taxol Konzentrat

Correlative studies

Given IV

Altri nomi:
  • Avastin
  • SOA 215
  • Anti-VEGF
  • Anticorpo monoclonale umanizzato anti-VEGF
  • Anticorpo monoclonale anti-VEGF SIBP04
  • Anti-VEGF rhuMAb
  • Bevacizumab awwb
  • Bevacizumab biosimilare ABP 215
  • Bevacizumab biosimilare BEVZ92
  • Bevacizumab biosimilare BI 695502
  • Bevacizumab biosimilare CBT 124
  • Bevacizumab biosimilare CT-P16
  • Bevacizumab biosimilare FKB238
  • Bevacizumab biosimilare GB-222
  • Bevacizumab biosimilare HD204
  • Bevacizumab biosimilare HLX04
  • Bevacizumab biosimilare IBI305
  • Bevacizumab biosimilare LY01008
  • Bevacizumab biosimilare MIL60
  • Bevacizumab biosimilare Mvasi
  • Bevacizumab biosimilare MYL-1402O
  • Bevacizumab biosimilare QL 1101
  • Bevacizumab biosimilare RPH-001
  • Bevacizumab biosimilare SCT501
  • Bevacizumab Biosimilare Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • BP102 Biosimilare
  • HD204
  • Immunoglobulina G1 (fattore di crescita endoteliale vascolare monoclonale umano-topo rhuMab-VEGF anti-catena gamma), disolfuro con catena leggera monoclonale umano-topo rhuMab-VEGF, dimero
  • Mvasi
  • MYL-1402O
  • Anticorpo monoclonale anti-VEGF umanizzato ricombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab biosimilare QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilare
  • Bevacizumab biosimilare BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-mal
  • Bevacizumab-onbe
  • CT P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab biosimilare MB02
  • Bevacizumab-tnjn
  • FKB238
  • FKB-238
  • MB02
  • MB-02
  • Oyavas
  • PF06439535
  • PF-06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305
Sperimentale: Arm II (paclitaxel, carboplatin, temsirolimus)

Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Given IV

Altri nomi:
  • Tassolo
  • Anzatax
  • Asotax
  • Bristaxolo
  • Praxel
  • Taxol Konzentrat

Correlative studies

Given IV

Altri nomi:
  • Torisel
  • CCI-779
  • Analogo della rapamicina CCI-779
  • Inibitore del ciclo cellulare 779
  • Analogo della rapamicina
  • CCI779
Sperimentale: Arm III (ixabepilone, carboplatin, bevacizumab)

Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Correlative studies

Given IV

Altri nomi:
  • Avastin
  • SOA 215
  • Anti-VEGF
  • Anticorpo monoclonale umanizzato anti-VEGF
  • Anticorpo monoclonale anti-VEGF SIBP04
  • Anti-VEGF rhuMAb
  • Bevacizumab awwb
  • Bevacizumab biosimilare ABP 215
  • Bevacizumab biosimilare BEVZ92
  • Bevacizumab biosimilare BI 695502
  • Bevacizumab biosimilare CBT 124
  • Bevacizumab biosimilare CT-P16
  • Bevacizumab biosimilare FKB238
  • Bevacizumab biosimilare GB-222
  • Bevacizumab biosimilare HD204
  • Bevacizumab biosimilare HLX04
  • Bevacizumab biosimilare IBI305
  • Bevacizumab biosimilare LY01008
  • Bevacizumab biosimilare MIL60
  • Bevacizumab biosimilare Mvasi
  • Bevacizumab biosimilare MYL-1402O
  • Bevacizumab biosimilare QL 1101
  • Bevacizumab biosimilare RPH-001
  • Bevacizumab biosimilare SCT501
  • Bevacizumab Biosimilare Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • BP102 Biosimilare
  • HD204
  • Immunoglobulina G1 (fattore di crescita endoteliale vascolare monoclonale umano-topo rhuMab-VEGF anti-catena gamma), disolfuro con catena leggera monoclonale umano-topo rhuMab-VEGF, dimero
  • Mvasi
  • MYL-1402O
  • Anticorpo monoclonale anti-VEGF umanizzato ricombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab biosimilare QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilare
  • Bevacizumab biosimilare BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-mal
  • Bevacizumab-onbe
  • CT P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab biosimilare MB02
  • Bevacizumab-tnjn
  • FKB238
  • FKB-238
  • MB02
  • MB-02
  • Oyavas
  • PF06439535
  • PF-06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Given IV

Altri nomi:
  • BMS-247550
  • Ixempra
  • (1S,3S,7S,10R,11S,12S,16R)-7,11-Diidrossi-8,8,10,12,16-pentametil-3-[(1E)-1-metil-2-(2- metil-4-tiazolil)etenil]-17-ossa-4-azabiciclo[14.1.0]eptadecan-5,9-dione
  • Azaepotilone B
  • BMS 247550
  • BMS247550
  • Epotilone
  • Epotilone-B BMS 247550

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants Who Progressed or Died by 25 Months From Enrollment
Lasso di tempo: at 25 months

PFS (Progression free survival) is defined as the duration of time from date of study entry to time of progression or death, whichever occurs first. Patients with a status of alive, progression-free are censored at their date of last follow-up. To lessen the potential for bias in the progression evaluation times between treatment arms and historical controls, progression/death times will be grouped over 6 18-week time intervals. Progressions are carried forward to the end of the interval. All progressions or deaths occurring after the 6th 18-week interval are censored at 25 months for this analysis. Study NCT00977574

at 25 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Frequenza e gravità della tossicità valutate da CTCAE v3.0 per ciascuno dei tre bracci.
Lasso di tempo: Mediana di 10 cicli di trattamento più 30 giorni
Mediana di 10 cicli di trattamento più 30 giorni
The Median Duration of Overall Survival for Each of the Three Arms.
Lasso di tempo: Time from date of study entry to time of death or the date of last contact, assessed up to 5 years

Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.

Time from date of study entry to time of death or the date of last contact, assessed up to 5 years
The Proportion of Patients With Measurable Disease Who Have Confirmed Objective Tumor Responses by Treatment.
Lasso di tempo: Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months

RECIST 1.1 was used to define objective tumor response. A complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. A partial response is defined as At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. There can be no unequivocal progression of non-target lesions and no new lesions. Complete and partial responses are included in the objective tumor response rate. Confirmation of response was not required.

Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Carol Aghajanian, NRG Oncology

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

14 settembre 2009

Completamento primario (Effettivo)

31 gennaio 2015

Completamento dello studio (Stimato)

6 marzo 2027

Date di iscrizione allo studio

Primo inviato

12 settembre 2009

Primo inviato che soddisfa i criteri di controllo qualità

12 settembre 2009

Primo Inserito (Stimato)

15 settembre 2009

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NCI-2011-01969
  • U10CA180868 (Sovvenzione/contratto NIH degli Stati Uniti)
  • U10CA027469 (Sovvenzione/contratto NIH degli Stati Uniti)
  • NCI-2011-01969 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • GOG-0086P (Altro identificatore: CTEP)
  • CDR0000654472
  • GOG-0086P
  • GOG-0086P (Altro identificatore: NRG Oncology)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .